The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
BUSINESS
Ivermectin Shows Antiviral Effects against Omicron: Kowa
Kowa said on January 31 that the antiparasitic agent ivermectin, which the company is developing for the treatment of COVID-19, has shown antiviral effects against the Omicron variant of the novel coronavirus in in-vitro testing. According to the company, its…
To read the full story
Related Article
- Ivermectin Fails in Investigator-Led COVID Trial Too
October 3, 2022
- Ivermectin Misses Goal in PIII COVID-19 Trial: Kowa
September 27, 2022
- MHLW to Fund Development of Kowa’s Ivermectin for COVID-19
March 7, 2022
- Ivermectin COVID-19 Trial Needed Because Evidence Is Lacking, Kowa Says as It Aims for PIII Wrap-Up in November
October 11, 2021
- Ivermectin to Enter 1st Company-Sponsored COVID-19 Trial in Japan
July 2, 2021
BUSINESS
- Organon CMO Calls for Balance between Innovation and Access to Longer-Listed Drugs
March 19, 2025
- Novartis CEO Touts Plan to Amp Up Japan Investment, Add 50 Jobs for Early Trials
March 18, 2025
- Takeda Settles on Wage Hike Similar to Last Year’s, Labor Union Disappointed
March 18, 2025
- Toa Out-Licenses Dry Eye Drug to South Korea’s JBK LAB
March 18, 2025
- Japan Approves Tablet Forms of Sleep Aid Melatobel: Nobelpharma
March 18, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…